Linked Life Data

1345676

Source:http://linkedlifedata.com/resource/pubmed/id/1345676

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-10-18
pubmed:abstractText
Over the past 10 years, very-high-dose cytotoxic therapy with rescue of marrow function by autologous bone marrow transplantation (BMT) has been shown to be effective treatment for patients with lymphomas and acute leukemias. However, a major concern has been that infusion of occult tumor cells with the autologous marrow will contribute to relapse. Accordingly, multiple techniques for treating autologous marrow grafts in vitro, to remove or "purge" occult tumor, have been developed. Despite controversy regarding the necessity and efficacy of purging, most autologous transplants for acute leukemia and many for lymphoma are currently purged. Most studies have used immunologic or cytotoxic agents for purging. The most widely used cytotoxic purging agents have been the cyclophosphamide congeners, 4-hydroperoxycyclophosphamide (4-HC) and mafosfamide. Since the first 4-HC-purged autologous marrow transplant was performed in 1980, over 700 patients have received 4-HC-purged autologous bone marrow transplants at Johns Hopkins alone. This review will chronicle the development of 4-HC as a purging agent.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1061-6128
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
343-8
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Purging with 4-hydroperoxycyclophosphamide.
pubmed:affiliation
Johns Hopkins Oncology Center, Baltimore, MD 21287-8967.
pubmed:publicationType
Journal Article, Review